Clinical study of lenalidomide combined with cyclophosphamide and low-dose dexamethasone on the treatment of multiple myeloma

VernacularTitle:来那度胺联合环磷酰胺、低剂量地塞米松治疗多发性骨髓瘤临床观察
Author: Chunhui HUANG
Keywords: Multiple myeloma; Pharmacotherapy; Lenalidomide; Cyclophosphamide; Dexamethasone
From: Chinese Journal of Postgraduates of Medicine 2017;40(8):690-692
CountryChina
Language:Chinese
Abstract: Objective To retrospectively analyze the therapeutic effect and adverse reactions of lenalidomide combined with cyclophosphamide and low-dose dexamethasone (RCD) in the treatment of multiple myeloma (MM). Methods Forty-five patients with MM was divided into treatment group (25 cases) and control group (20 cases) according to non-randomized concurrent control method: the former was treated by RCD, and the latter accepted melphalan combined with prednison and thalidomide (MPT). Results The overall response rates (ORR) for the treatment group and the control group were 84.0%(21/25) and 65.0%(13/20)respectively (P > 0.05), and high quality response (CR + VGPR) rates were 64.0%(16/25) and 30.0%(6/20) respectively (P<0.05). The relapse rates and 3-year overall survival rates were 24.0%(6/25) and 55.0%(11/20), 76.0%(19/25) and 45.0%(9/20), respectively (P<0.05). Compared with those of the control group, the incidence of thrombopenia and neutropenia was higher, and treatment-related toxicities were lower in treatment group (P<0.05). Conclusions RCD may be more effective, and adverse reactions can be tolerated. The therapy method is worthy to be recommended.